// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

Extensively hydrolysed formula with two human milk oligosaccharides reduces rate of upper respiratory tract infections in infants with cow's milk allergy

Vandenplas Y - European Academy of Allergy and Clinical Immunology (EAACI) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Conventional immunotherapy vs nano‐vaccination in high risk allergy

Kramer MF - European Academy of Allergy and Clinical Immunology (EAACI) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Safety and tolerability of a subcutaneously administered tyrosine adsorbed modified mites allergen MIX + MPL

Roger A - European Academy of Allergy and Clinical Immunology (EAACI) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

L-Tyrosine

Glyco‐engineering and IgG‐Fc mutations to improve efficacy of monoclonal antibody therapy for breast cancer

Chenoweth A - European Academy of Allergy and Clinical Immunology (EAACI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Trastuzumab

Evaluating a method validation to deplete, purify and determine the function of IgG4, IgA1 and IgA2 antibodies induced following sublingual immunotherapy in patients with allergic rhinitis

Parkin RV - European Academy of Allergy and Clinical Immunology (EAACI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Allergic rhinitis

N/A

Establishing a Th2 and Tfh cell exhaustion in vitro model using TCR Signaling to test T cell anergy during immunotherapy

Zhu R - European Academy of Allergy and Clinical Immunology (EAACI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Allergic rhinitis

N/A

EAACI Task Force Logogram: Anaphylaxis decision tools to facilitate the diagnosis and management of anaphylaxis in primary care

Mamodaly M - European Academy of Allergy and Clinical Immunology (EAACI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Anaphylaxis

N/A

Pollen food allergy syndrome in seven southern European countries: Results from the @IT2020 multicenter study

Lipp T - European Academy of Allergy and Clinical Immunology (EAACI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Allergic rhinitis

N/A

Predicting systemic mastocytosis in patients with severe anaphylaxis—A UK single centre experience

Oni C - European Academy of Allergy and Clinical Immunology (EAACI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Mastocytosis

N/A

YoaJ, an expansin‐like protein from Bacillus subtilis, is a non‐allergenic structural homologue of the major grass pollen allergen Phl p 1

Radauer C - European Academy of Allergy and Clinical Immunology (EAACI) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

The role of interleukin 3 (IL3) in allergic asthma

Klle J - European Academy of Allergy and Clinical Immunology (EAACI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

Interleukin

Differences in induction of asthma‐relevant pro‐inflammatory mediators by β2‐agonists and muscarinic antagonists in human bronchial epithelial cells

Kumar K - European Academy of Allergy and Clinical Immunology (EAACI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

Umeclidinium

The role of regulated on activation, normal T cell expressed and secreted (RANTES) in allergic asthma

Li N - European Academy of Allergy and Clinical Immunology (EAACI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

N/A

NK cells in the pathogenesis of obese asthma phenotypes

Pur Ozyigit L - European Academy of Allergy and Clinical Immunology (EAACI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

N/A

Sphingosine‐1‐phosphate induces constriction and hyperresponsiveness in ex vivo human airways

Maguire TJA - European Academy of Allergy and Clinical Immunology (EAACI) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Role of nuclear factor of activated T cells 2 (NFATc2) in allergic asthma

Jakobi M - European Academy of Allergy and Clinical Immunology (EAACI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

N/A

Biochemical regulation of the Tim‐3‐galectin‐9 immunosuppressive pathway

Seln ATH - European Academy of Allergy and Clinical Immunology (EAACI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute myelocytic leukemia

N/A

AllergoOncology: Study of potential hypersensitivity to an anti‐tumor IgE therapeutic candidate in a diverse cohort of ovarian cancer patients using a basophil activation test

Bax HJ - European Academy of Allergy and Clinical Immunology (EAACI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gynaecological cancer

N/A

What is the value of test‐guided dietary advice for children with eczema? Trial of eczema allergy screening tests (TEST) feasibility randomised controlled trial (RCT) with nested qualitative study

Ridd MJ - European Academy of Allergy and Clinical Immunology (EAACI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Atopic Dermatitis

N/A

Assessing the management of Eczema Herpeticum in children with Atopic Dermatitis

Thotapalli V - European Academy of Allergy and Clinical Immunology (EAACI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Atopic Dermatitis

N/A

Copyright © 2026. QuantiNova All rights reserved